APC 366

• Description:

  APC 366 is a selective inhibitor of mast cell tryptase (Ki=7.1 μM) . APC 366 inhibits antigen-induced early asthmatic response (EAR), late asthmatic response (LAR), and bronchial hyperresponsiveness (BHR) in a sheep model of allergic asthma[1][2].

• UNSPSC:

  12352005

• Target:

  Ser/Thr Protease

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/apc-366.html

• Purity:

  99.81

• Solubility:

  10 mM in DMSO

• Smiles:

  OC1=C(C(N[C@@H](CCCNC(N)=N)C(N2[C@@H](CCC2)C(N)=O)=O)=O)C=CC3=C1C=CC=C3

• Molecular Formula:

  C22H28N6O4

• Molecular Weight:

  440.50

• References & Citations:

  [1]Barrios VE, et al. Tryptase mediates hyperresponsiveness in isolated guinea pig bronchi. Life Sci. 1998;63 (26) :2295-2303. |[2]Krishna MT, et al. Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma. J Allergy Clin Immunol. 2001;107 (6) :1039-1045.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [158921-85-8]